Trial Profile
Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Ceralasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Anthracyclines
- Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PARTNER
- 09 Nov 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2034.
- 09 Nov 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jun 2024.
- 07 Jun 2022 Since May 2016, 756 patients from 30 sites have been enrolled. Stage 3 phase I (recruitment of non-gBRCA and gBRCA patients) completed December 2021. Stage 3 phase II (recruitment of gBRCA patients) remains open to patients in the U.K. and internationally. 5 patients have enrolled in PARTNERING. Follow-up duration is 10 years as reported in trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology